We're in the FINAL hours!⌛

Only 12 hours left to submit your #NLASessions abstract. Submissions close TONIGHT at 11:59 PM ET. No extensions!

Submit now👉 lipid.org/abstracts

Final weekend reminder!⏰

This is the last chance to work on and submit your #NLASessions abstract. Take advantage of the extension and make sure your research is part of lipidology’s premier scientific meeting.

The deadline is Monday — don’t wait.
👉Submit now: lipid.org/lipidinsights

🚨Deadline Extended!🚨

You now have until January 12 at 11:59 PM ET to submit your abstract for the 2026 #NLASessions. Take advantage of this extension and make sure your research is part of the premier meeting in lipidology!

🔗Submit now: lipid.org/abstracts

Abstracts for the 2026 #NLASessions are due in ONE WEEK!⏳

If you have lipidology research to share, THIS is your moment. Don’t miss the chance to showcase your work and be part of the science shaping the future of lipid care.

Submission portal👉lipid.org/abstracts

Submit your abstract for the 2026 #NLASessions and be part of the science shaping lipidology!

Accepted abstracts will be featured in the #NLASessions Poster Hall and published in the Journal of Clinical Lipidology.

Two weeks left to submit! Don't wait👉lipid.org/abstracts

@nationallipid.bsky.social #NLASessions Dr Kalra discussing his trial of usual care versus very high intensity lipid lowering based on plaque Alaysis—ARTCAP TRIAL

📣In case you missed it at #NLASessions: The NLA released its Expert Clinical Review on Multidisciplinary Teams in Clinical Lipidology and Cardiometabolic Care.🩺🫀

Read the article & download the clinician infographic: ow.ly/poRE50W4smS

@nationallipid.bsky.social #NLASessions Coronary perivascular fat is a biomarker for CV risk

We’re excited to see data from our Phase 3 BROADWAY study shared in a late-breaking oral presentation at #NLASessions. Discover what we’ve learned in this study of 2,500 patients at high risk for cardiovascular disease. www.newamsterdampharma.com/wp-content/u...

Impact of the Cholesteryl Ester Transfer Protein Inhibitor, Obicetrapib, on Lipoprotein(a) Levels: Pooled Data From Phase 3 Clinical Trials

A pooled analysis from three of our Phase 3 studies evaluated obicetrapib’s effect on Lp(a) in people at increased risk for cardiovascular disease, particularly in those with baseline Lp(a) from 50-150 nmo/L. See the data shared at #NLASessions: www.newamsterdampharma.com/wp-content/u...

@nationallipid.bsky.social #NLASessions DrRay teaching us about CTEP inhibition

Click the link to view the poster: Effect of Obicetrapib on New-Onset Diabetes in Patients With Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the BROADWAY and BROOKLYN Trials

New at #NLASessions: An analysis of pooled data from our Phase 3 program related to obicetrapib’s impact on HbA1c and new onset diabetes in patients with prediabetes and normoglycemia at baseline on a background of mostly high-intensity statins. See the poster: bit.ly/4jnLLkb

NLA Scientific Sessions Encore Presentations of BROADWAY and BROOKLYN

Data from two of our completed Phase 3 studies—BROOKLYN and BROADWAY—are coming back for an encore at #NLASessions! Learn about the efficacy, safety, and tolerability of our lead investigational asset in populations at high risk for cardiovascular disease. bit.ly/4dDiWz3

Counting down till #NLASessions. Register now to join us for breakfast and CME on Friday!
vindicoce.com/NLA

NLA Scientific Sessions

We're eager to touch down in Miami for #NLASessions, where insights from two of our completed Phase 3 studies—BROOKLYN and BROADWAY—will be shared along with 9 additional analyses. We hope to see you in The Magic City next week! @nationallipid.bsky.social

CE Breakfast Symposium during #NLASessions Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk Friday, May 30 at 7:15 AM

🍳 FREE CME + breakfast + the latest breakthroughs in #ASCVD treatment

Fri, May 30 | 7:15–8:45 AM at JW Marriott Miami Turnberry Resort and Spa #NLASessions

🔗 vindicoce.com/NLA

@nationallipid.bsky.social @erinmichos.bsky.social @foundationofnla.bsky.social @lipidjournal.bsky.social

Don’t miss the CETP comeback story—plus RAPID-FIRE ROUNDTABLE—at our CE breakfast on May 30 during #NLASessions Register here >> vindicoce.com/NLA
@erinmichos.bsky.social
@nationallipid.bsky.social
@lipidjournal.bsky.social
@foundationofnla.bsky.social

CE Breakfast Symposium at #NLASessions

Excited to be a part of #NLASessions! We're bringing an exciting #CE breakfast symposium on CETP inhibitors on Fri 5/30. Register here: vindicoce.com/NLA

#ASCVD #lipid #lipidology #cardiovasculardisease #dyslipidemia #MedSky @nationallipid @Lipidjournal @Foundationofnla @erinmichos.bsky.social

Register for #NLASessions to join!
🔗 lipid.org/sessions

When you see your 🔥 cardiology #bestie listed as #NLASessions faculty and you can’t wait to learn from her! @aneeshathobani @nationallipid

What a pleasure to contribute to the @nationallipid Scientific Statement on Statin Intolerance with a great team! @JSaseenPharmD @DaveDixonPharmD et al. #NLAsessions #CardioTwitter

What a pleasure to contribute to the @nationallipid Scientific Statement on Statin Intolerance with a great team! @JSaseenPharmD @DaveDixonPharmD et al. #NLAsessions #CardioTwitter

Aortic stenosis disproportionately burdens individuals with familial hypercholesterolemia and high Lp(a).

One facet of #CVPrev includes screening for premature #VHD and referring for treatment.

Beautifully presented,@NathanBekeleMD of @WashUIMRes
#NLASessions #DrAnneGoldberg

Aortic stenosis disproportionately burdens individuals with familial hypercholesterolemia and high Lp(a).

One facet of #CVPrev includes screening for premature #VHD and referring for treatment.

Beautifully presented,@NathanBekeleMD of @WashUIMRes
#NLASessions #DrAnneGoldberg

There is an urgent need to focus on implementation of evidence- based therapies among South Asian patients - @nihardesai927

Insightful discussions at the #NLASessions @nationallipid @DineshKalra @alka_kanaya @NammiKan

There is an urgent need to focus on implementation of evidence- based therapies among South Asian patients - @nihardesai927

Insightful discussions at the #NLASessions @nationallipid @DineshKalra @alka_kanaya @NammiKan

Primary prevention focused on hypertension and smoking cessation is key to reduce the burden of ASVD in black patients with familial hypercholesterolemia.

Stellar @WUDeptMedicine IM resident, Dr. Nathan Bekele presents at the #NLASessions! #DrAnneGoldberg #KnowFH

Primary prevention focused on hypertension and smoking cessation is key to reduce the burden of ASVD in black patients with familial hypercholesterolemia.

Stellar @WUDeptMedicine IM resident, Dr. Nathan Bekele presents at the #NLASessions! #DrAnneGoldberg #KnowFH

Fabulous talk on familial chylomicronemia syndrome by my beloved mentor #DrAnneGoldberg
@WUSTL @WUDeptMedicine @wustlcardfellow #NLASessions @nationallipid

Fabulous talk on familial chylomicronemia syndrome by my beloved mentor #DrAnneGoldberg
@WUSTL @WUDeptMedicine @wustlcardfellow #NLASessions @nationallipid